Loading...
Loading...
Contributors:
Dataset URI:
10.1371/journal.pone.0351131.s003Iscalimab is a nondepleting anti-CD40 monoclonal antibody, expected to suppress immune responses by blocking the costimulation by antigen-presenting cells through CD40-CD40L ligation. This therapeutic antibody indeed inhibited proliferation of B lymphocytes and TNF production by dendritic cells and is being tested in clinical trials to treat B cell mediated autoimmune diseases. Since iscalimab showed limited clinical benefit and did not improve kidney and liver transplantation outcomes compared to standard tacrolimus treatment, we studied whether a biosimilar of iscalimab affects T cell responses in vitro. For this, we stimulated autoreactive effector and alloreactive naïve CD4 T cells in the presence of anti-CD40 antibody and measured the impact on cell proliferation. While we confirmed the capacity of iscalimab biosimilar antibody to bind to B cells and dendritic cells and to completely inhibit proliferating B cells, it showed limited to no efficacy to inhibit proliferation of diabetogenic beta-cell specific effector CD4 T cell clones. The CD40 blockade also did not affect the induction of proliferation of naïve alloreactive CD4 T cells, by dendritic cells. Based on our in vitro data pointing to minimal inhibition of T cells by CD40 blockade, we propose that iscalimab may not suffice to accomplish durable benefit as intervention strategy to treat type 1 diabetes or other T cell mediated diseases.
Keyword(s):
accomplish durable benefit; alloreactive cd4; b lymphocytes; Biological Sciences not elsewhere classified; Biotechnology.
MeSH Term(s):
Grants and Funding:
No Grants or Funding Data Available
Associated Publication(s):
Supplementary Data:
No Supplementary Data Available
Related Dataset(s):
No Related Dataset Data Available
The National Library of Medicine (NLM) provides information about biomedical datasets. Inclusion on an NLM Web page does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: NLM Web Policies (nih.gov)